Multimodal MRI markers of nigrostriatal pathology in Parkinson's disease

帕金森病黑质纹状体病理的多模态 MRI 标记

• 批准号: 8473552
• 负责人: XUEMEI HUANG
• 金额: $ 64.95万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-30 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8473552
• 关键词: Affect; Age; Amyloid; Amyloid beta-Protein; Anisotropy; Autopsy; Basal Ganglia; Biochemical; Biological; Biological Markers; Blood; Body Fluids; Brain; Cells; Clinical; Clinical Trials; Communities; Corpus striatum structure; Data; Data Correlations; Deposition; Detection; Diagnosis; Diagnostic tests; Diffusion; Discrimination; Disease; Disease Progression; Dopamine; Exposure to; Ferritin; Functional disorder; Future; Gender; Growth Factor; Handedness; Histopathology; Homeostasis; Image; Imaging Techniques; Individual; Inflammation; Iron; Lead; Lewy Bodies; Link; Liquid substance; Magnetic Resonance Imaging; Measurement; Measures; Metabolism; Multiple System Atrophy; Myelin; National Institute of Neurological Disorders and Stroke; Neuroglia; Neurons; Onset of illness; Parkinson Disease; Parkinsonian Disorders; Pathologic Processes; Pathology; Patients; Physiological Processes; Population; Positron-Emission Tomography; Progressive Supranuclear Palsy; Proteins; Radioactivity; Reporting; Research; Research Infrastructure; Research Personnel; Resolution; Role; Sensitivity and Specificity; Staging; Staining method; Stains; Structure; Substantia nigra structure; Techniques; Technology; Testing; Tissues; Tyrosine 3-Monooxygenase; Ubiquitin; Urine; Work; base; behavior measurement; clinical Diagnosis; density; disorder control; dopaminergic neuron; falls; hepcidin; in vivo; insight; neurobehavioral; neuron loss; nigrostriatal pathway; pars compacta; programs; protein profiling; single photon emission computed tomography; success; synuclein; tau Proteins; therapeutic target

DESCRIPTION (provided by applicant): Parkinson's disease (PD) is marked pathologically by dopamine neuronal loss in the substantia nigra (SN) of the basal ganglia (BG) and the presence of Lewy bodies. The lack of in vivo biomarker(s) reflecting PD-related cell loss and associated pathoetiological/physiological processes has hindered discovery research and limited the ability to evaluate potentially disease-modifying therapies. The best available technology, radioimaging using 18FDOPA-PET and [123I]b-CIT SPECT, can assess the activity or density of striatal dopamine terminals. These techniques, however, do not reflect directly the pathological process in the SN, may not distinguish PD from other parkinsonian syndromes, and can be affected by symptomatic therapy. In addition, both techniques require exposure to radioactivity and PET requires facilities not widely available. Magnetic resonance imaging (MRI) is noninvasive, easily accessible, and widely available, yet its measures have been difficult to relate to a specific pathophysiological mechanism. Diffusion tensor (DTI) and R2* imaging have been reported to detect changes in the SN in PD, and offer the promise of being MRI biomarkers. There is, however, a lack of understanding of their clinical implications and biological/pathological underpinnings. Our pilot data support the hypothesis that fractional anisotropy (FA) and R2* measures reflect different aspects of nigrostriatal pathology that can be used as biomarkers for diagnosing PD and following its progression. We propose to leverage the longitudinal clinical population and existing infrastructure of the PI's R01 (2009-2014) to test the above hypothesis. In addition, we have considerable expertise in developing disease biomarkers, particularly related to iron (Fe) metabolism. By melding in vivo high-resolution DTI and R2* MRI data with assessment of Fe-related protein profiles in body fluids, we expect to gain marked insight into predicting PD progression. Moreover, our strengths in postmortem brain histopathology and analysis of Fe-related proteins will permit the correlation of the in vivo clinical and brain MRI measures with biochemical changes in the brain. This will provide a mechanistic understanding of the role of Fe in PD that may lead to the discovery of new biomarkers or therapeutic targets. Based on power analysis pilot data, four aims will be performed: 1) Establish the differential roles of DTI and R2* in PD detection and progression; 2) Demonstrate that nigrostriatal DTI and R2* differentiate PD from parkinsonian syndromes; 3) Interrogate Fe-related proteins in body fluids as biomarkers; 4) Obtain MRI biomarker and postmortem pathological correlation data. The success of the study shall yield valid markers for both detection of PD and its progression that can be integrated into and hopefully impact disease-modifying clinical trials within the foreseeable future. The clinical and MRI data and the biosamples collected and deposited to the DMR of the PDBP shall provide investigators in the biomarker community the opportunity to explore and understand changes outside of nigrostriatal pathways and non Fe-related proteins and their relationship with our proposed markers. PUBLIC HEALTH RELEVANCE: The lack of in vivo biomarker(s) reflecting Parkinson's disease (PD)-related cell loss and associated pathoetiological/physiological processes in nigrostriatal structures has hindered discovery research and limited the ability to evaluate disease-modifying therapies. Recent research has generated excitement for using DTI and R2* MRI measures as biomarker(s) for PD-related pathology in nigrostriatal pathways, but they fall short by the lack of understanding of their clinical implications and biological/pathological underpinnings. Working closely with the NINDS Parkinson's Disease Biomarkers Program (PDBP), the proposed work will investigate multimodal MRI techniques in combination with fluid-based iron (Fe) protein profiles to serve as in vivo markers for PD-related nigrostriatal pathology that can be used as biomarkers for diagnosing PD, following its progression, and gaining mechanistic understanding of PD pathoetiology and pathophysiology.

描述（由申请方提供）：帕金森病（PD）的病理特征是基底神经节（BG）黑质（SN）中的多巴胺神经元丢失和路易体的存在。缺乏反映PD相关细胞丢失和相关病理/生理过程的体内生物标志物阻碍了发现研究，并限制了评价潜在疾病缓解疗法的能力。最好的技术，放射成像使用18FDOPA-PET和[123 I]b-CIT SPECT，可以评估纹状体多巴胺末梢的活性或密度。然而，这些技术不能直接反映SN的病理过程，可能无法将PD与其他帕金森综合征区分开来，并且可能受到对症治疗的影响。此外，这两种技术都需要暴露于放射性，而PET需要的设施并不广泛。磁共振成像（MRI）是无创的，容易获得，广泛使用，但它的措施一直难以涉及到一个特定的病理生理机制。已报道扩散张量（DTI）和R2* 成像可检测PD患者SN的变化，并有望成为MRI生物标志物。然而，缺乏对其临床意义和生物学/病理学基础的了解。我们的试点数据支持的假设，分数各向异性（FA）和R2* 措施反映了黑质纹状体病理学的不同方面，可用作诊断PD和以下其进展的生物标志物。我们建议利用PI R 01（2009-2014）的纵向临床人群和现有基础设施来检验上述假设。此外，我们在开发疾病生物标志物方面拥有相当丰富的专业知识，特别是与铁（Fe）代谢相关的生物标志物。通过融合体内高分辨率DTI和R2* MRI数据与体液中铁相关蛋白质谱的评估，我们期望获得预测PD进展的显着见解。此外，我们在死后脑组织病理学和铁相关蛋白分析的优势将允许在体内的临床和脑MRI测量与脑中的生化变化的相关性。这将提供对Fe在PD中的作用的机制理解，这可能导致发现新的生物标志物或治疗靶点。基于功效分析初步数据，将执行四个目标：1）建立DTI和R2* 在PD检测和进展中的区别作用; 2）证明黑质纹状体DTI和R2* 区分PD和帕金森综合征; 3）询问体液中的铁相关蛋白作为生物标志物; 4）获得MRI生物标志物和死后病理相关性数据。该研究的成功将产生用于PD检测及其进展的有效标志物，这些标志物可以整合到可预见的未来的疾病改善临床试验中，并有望影响这些试验。临床和MRI数据以及收集并保存到PDBP DMR的生物样本应向生物标志物社区的研究者提供探索和了解黑质纹状体途径和非铁相关蛋白以外的变化及其与我们提出的标志物的关系的机会。 公共卫生关系：在黑质纹状体结构中缺乏反映帕金森病（PD）相关细胞损失和相关病理病因学/生理学过程的体内生物标志物阻碍了发现研究并限制了评估疾病修饰疗法的能力。最近的研究对于使用DTI和R2* MRI测量作为黑质纹状体通路中PD相关病理学的生物标志物产生了兴奋，但是由于缺乏 了解其临床意义和生物学/病理学基础。与NINDS帕金森病生物标志物计划（PDBP）密切合作，拟议的工作将研究多模式MRI技术与基于液体的铁（Fe）蛋白质谱相结合，作为PD相关黑质纹状体病理学的体内标志物，可用作诊断PD的生物标志物，遵循其进展，并获得对PD病因学和病理生理学的机械理解。